4,4'-(1H-pyrazole-3,4-diyl)bis[pyridine] | 216507-35-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4,4'-(1H-pyrazole-3,4-diyl)bis[pyridine]
• 英文别名: 4-(4-pyridin-4-yl-1H-pyrazol-5-yl)pyridine
• CAS: 216507-35-6
• 化学式: C₁₃H₁₀N₄
• 分子量: 222.249
• InChiKey: TZKYQYVSUJBNOL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] PYRAZOLE DERIVATIVES AS MODULATORS OF THE WNT/B-CATENIN SIGNALING PATHWAY<br/>[FR] DÉRIVÉS DE PYRAZOLE UTILISÉS COMME MODULATEURS DE LA VOIE DE SIGNALISATION WNT/β-CATÉNINE
  申请人：SAMUMED LLC

  公开号：WO2020150545A1

  公开（公告）日：2020-07-23

  Pyrazole compounds (I) for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a pyrazole compounds, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

  本发明涉及用于治疗各种疾病和病理的吡唑化合物（I）。更具体地，本公开涉及使用吡唑化合物，在治疗通过激活Wnt途径信号特征的疾病（例如癌症、异常细胞增殖、血管生成、阿尔茨海默病、肺部疾病、炎症、自身免疫疾病和骨关节炎）中，调节由Wnt途径信号介导的细胞事件，以及与DYRK1A过度表达相关的神经症状/疾病。
• Substituted pyrazoles as p38 kinase inhibitors
  申请人：——

  公开号：US20040176433A1

  公开（公告）日：2004-09-09

  A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula IA 1 wherein R 1 , R 2 , R 3 and R 4 are as described in the specification.

  本文描述了一类吡唑衍生物，用于治疗p38激酶介导的疾病。特别感兴趣的化合物由公式IA1定义，其中R1、R2、R3和R4如规范中所述。
• Substituted pyrazoles as P38 kinase inhibitors
  申请人：G.D. Searle LLC

  公开号：EP1500657A1

  公开（公告）日：2005-01-26

  A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula (IA), wherein R1, R2, R3 and R4 are as described in the specification.

  描述了一类吡唑衍生物用于治疗 p38 激酶介导的疾病。特别感兴趣的化合物由式（IA）定义、 其中 R1、R2、R3 和 R4 如说明书所述。
• SUBSTITUTED PYRAZOLES AS P38 KINASE INHIBITORS
  申请人：G.D. Searle LLC

  公开号：EP1144403B1

  公开（公告）日：2004-10-06
• CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES
  申请人：Electrophoretics Limited

  公开号：US20160354375A1

  公开（公告）日：2016-12-08

  The invention relates to pharmaceutical compositions comprising casein kinase 1 delta (CK1δ) and to the use of said inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.